Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT16...Read more

The high effectiveness of the third dose of BNT162b2 in healthy adolescents against Omicron BA.1 has been reported in some studies, but immune respons...Read more

Background: Omicron subvariant BA.2 circulation is rapidly increasing globally. Aim: We evaluated the neutralising antibody response from vaccination ...Read more

The Department of Paediatrics and Adolescent Medicine and School of Public Health at HKUMed are now launching the COVID-19 Vaccination in Adolescents ...Read more

We administered BNT162b2 as a third dose to 314 adults aged ≥30 years who had previously received 2 doses of inactivated vaccine. We collected blood s...Read more

Introduction: Two doses of inactivated SARS-CoV-2 vaccine CoronaVac cannot elicit high efficacy against symptomatic COVID-19, especially against the O...Read more

An international research team from the University of Hong Kong, the Laboratory of Data Discovery for Health, and the Centre for Immunology & Infectio...Read more

Background: Limited data exist on antibody responses to mixed vaccination strategies that involve inactivated coronavirus disease 2019 (COVID-19) vacc...Read more

Background: BA.2.12.1, BA.4 and BA.5 subvariants of SARS-CoV-2 variant-of-concern (VOC) Omicron (B.1.1.529) are spreading globally. They demonstrate h...Read more

The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and escape of vaccine-derived immunity. Although first-generation vaccines r...Read more

The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally. It is important to define reductions in virus neutralizing...Read more

Few trials have compared homologous and heterologous third doses of COVID-19 vaccination with inactivated vaccines and mRNA vaccines. The aim of this ...Read more